Breaking News Instant updates and real-time market news.

ISRG

Intuitive Surgical

$709.44

-5.47 (-0.77%)

, TRXC

TransEnterix

$1.85

-0.0099 (-0.53%)

14:08
10/18/16
10/18
14:08
10/18/16
14:08

On The Fly: What to watch in Intuitive Surgical earnings report

Intuitive Surgical (ISRG) is scheduled to report results of its third fiscal quarter after the market close on October 18, with a conference call scheduled for 4:30 pm EDT. What to watch for: 1. PROCEDURAL GROWTH: Along with its second quarter report, Intuitive Surgical raised its much watched procedural growth view for its daVinci system to 14%-15% from 12%-14%. On July 20, the day after Intuitive Surgical's second quarter report, research firm Stifel increased its price target on Intuitive Surgical after the company's products carried out more procedures than expected in Q2 and its financial results beat expectations. The firm said at the time it thinks that the company's procedure growth and gross margin guidance could prove conservative even after they were increased on the Q2 earnings call. The firm said that the company's pipeline is gaining momentum, and it kept a Buy rating on the shares. 2. COMPETITOR PROBLEMS. On April 20, another robotic surgery company, TransEnterix (TRXC), which industry experts viewed as a growing competitive threat to Intuitive Surgical, announced that the FDA determined the company's SurgiBot System does not meet the criteria for substantial equivalence based upon the data and information submitted by TransEnterix in its 510(k) submission. "The FDA's decision is extremely disappointing. We are in the process of reviewing all aspects of the FDA's communication," said Todd Pope, president and CEO of TransEnterix. A day later on April 21, Piper Jaffray analyst Matt O'Brien concluded that TransEnterix's announcement that the FDA had rejected the 510 submission for its SurgiBot robotic system as a incremental positive for Intuitive Surgical. The delay may impact both the ongoing European launch and the upcoming domestic introduction of TransEnterix's more feature-rich ALF-X product, O'Brien told investors in a research note. At the time, he said he believed TransEnterix is the biggest near-term competitive threat to Intuitive. O'Brien kept a Neutral rating on Intuitive Surgical due to valuation. 3. HERNIA OPPORTUNITY: During its earnings conference call last quarter, the company's chief executive officer Gary Guthart commented on the opportunity it sees in hernia repair: "Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of daVinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance." On September 19, Leerink analyst Richard Newitter said he left the Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's general surgery division, Newitter told investors in a research note. He reiterated an Outperform rating on the shares with a $780 price target.

ISRG

Intuitive Surgical

$709.44

-5.47 (-0.77%)

TRXC

TransEnterix

$1.85

-0.0099 (-0.53%)

  • 18

    Oct

  • 29

    Nov

ISRG Intuitive Surgical
$709.44

-5.47 (-0.77%)

09/15/16
SBSH
09/15/16
NO CHANGE
SBSH
Buy
New prostate study a positive for Intuitive Surgical, says Citi
Citi analyst Amit Hazan noted that a new study published in the New England Journal of Medicine found no difference in mortality between prostrate cancer patients treated with surgery or radiation and those placed on active monitoring after 10 years. However, men assigned to active monitoring were significantly more likely to have metastatic disease, Hazan highlighted, calling the study a positive for Intuitive Surgical, as it may help doctors "swing the pendulum" back to treatment. The analyst, who thinks Intuitive's da Vinci Prostatectomy procedures can grow above incidence rates for several years, keeps a Buy rating on the stock.
09/19/16
LEER
09/19/16
NO CHANGE
Target $780
LEER
Outperform
Leerink positive on Intuitive Surgical's hernia opportunity
Leerink analyst Richard Newitter says he left this weekend's Annual Global Symposium on Robotic-Assisted and Minimally Invasive Hernia Repair "incrementally more positive" on the adoption outlook for Intuitive Surgical's robotic hernia category. Hernia can remain a source of upside for the company's gen surgery division, Newitter tells investors in a research note. He reiterates an Outperform rating on the shares with a $780 price target.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $779
SBSH
Buy
Intuitive Surgical procedure upside looks likely, says Citi
Following his firm's semi-annual urology survey and gynecology survey, Citi analyst Amit Hazan believes more procedure upside for Intuitive Surgical looks likely. The results point to continued strength in Intuitive's legacy categories that make up nearly 70% of its U.S. procedures, Hazan tells investors in a research note. He keeps a Buy rating on the shares with a $779 price target.
10/13/16
WELS
10/13/16
INITIATION
WELS
Outperform
Intuitive Surgical initiated with an Outperform at Wells Fargo
Wells Fargo analyst Larry Biegelsen started Intuitive Surgical with an Outperform rating and $815-$825 price target range. The analyst expects continued adoption of hernia repair and colorectal procedures to drive "strong growth" in the United States and views the company's international opportunity as underappreciated. Biegelsen sees "several reasons" for why Intuitive's share outperformance to continue.
TRXC TransEnterix
$1.85

-0.0099 (-0.53%)

04/21/16
PIPR
04/21/16
NO CHANGE
PIPR
Neutral
TransEnterix rejection a positive for Intuitive Surgical, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views TransEnterix's (TRXC) announcement that the FDA had rejected the 510 submission for its SurgiBot robotic system as a incremental positive for Intuitive Surgical (ISRG). The delay may impact both the ongoing European launch and the upcoming domestic introduction of TransEnterix's more feature-rich ALF-X product, O'Brien tells investors in a research note. The analyst believes TransEnterix is the biggest near-term competitive threat to Intuitive. O'Brien keeps a Neutral rating on Intuitive Surgical due to valuation.
04/21/16
RBCM
04/21/16
NO CHANGE
RBCM
TransEnterix price target lowered to $4 from $6 at RBC Capital
RBC Capital cut its price target on TransEnterix after the FDA decided not to approve the company's application for its SurgiBot product. However, the firm thinks the company's ALF-X system could be successful, and it keeps an Outperform rating on the name.
05/11/16
LSCM
05/11/16
DOWNGRADE
Target $2
LSCM
Hold
TransEnterix downgraded to Hold from Buy at Lake Street
Lake Street analyst Bruce Jackson downgraded TransEnterix to Hold saying he prefers to wait on the sidelines until the SurgiBot issues are resolved. The analyst has a $2 price target for the shares.
10/07/16
RILY
10/07/16
INITIATION
Target $3
RILY
Buy
TransEnterix initiated with a Buy at B. Riley
B. Riley analyst Greg Chodaczek started TransEnterix with a Buy rating and $3 price target. The analyst sees a large market opportunity for robotic-assisted surgical systems.

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Hot Stocks
Procter & Gamble says commodity costs have moved up this year »

Says seeing some growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

PXD

Pioneer Natural

09:19
01/23/18
01/23
09:19
01/23/18
09:19
Recommendations
Pioneer Natural analyst commentary  »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

TYL

Tyler Technologies

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Hot Stocks
Tyler Technologies selected by Orlando, Florida for public safety solution »

Tyler Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PE

Parsley Energy

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Recommendations
Parsley Energy analyst commentary  »

Parsley Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    May

SPX

S&P 500

, VIX

Volatility Index S&P 500 Options

09:18
01/23/18
01/23
09:18
01/23/18
09:18
Options
Overnight activity included 92 trades in SPX and 25 trades in VIX »

92 trades were executed…

SPX

S&P 500

VIX

Volatility Index S&P 500 Options

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

, LOGI

Logitech

$37.58

0.25 (0.67%)

09:17
01/23/18
01/23
09:17
01/23/18
09:17
Hot Stocks
On The Fly: Pre-market Movers »

UP AFTER EARNINGS:…

VZ

Verizon

LOGI

Logitech

$37.58

0.25 (0.67%)

JNJ

Johnson & Johnson

NFLX

Netflix

$227.58

7.12 (3.23%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

KMB

Kimberly-Clark

RMD

ResMed

AMTD

TD Ameritrade

$55.88

0.71 (1.29%)

ATI

Allegheny Technologies

TSLA

Tesla

$351.56

1.54 (0.44%)

AAPL

Apple

$177.00

-1.46 (-0.82%)

PG

Procter & Gamble

ADMS

Adamas Pharmaceuticals

$40.79

2.6 (6.81%)

GPRO

GoPro

$6.30

0.01 (0.16%)

TWTR

Twitter

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 30

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 08

    Feb

  • 16

    Feb

  • 16

    Feb

  • 28

    Feb

  • 08

    Mar

  • 24

    Jan

NBL

Noble Energy

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Recommendations
Noble Energy analyst commentary  »

Noble Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

JNJ

Johnson & Johnson

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Hot Stocks
Johnson & Johnson sees apalutamide approval in 2018 »

Johnson & Johnson CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

ABEO

Abeona Therapeutics

$14.85

0.25 (1.71%)

09:16
01/23/18
01/23
09:16
01/23/18
09:16
Initiation
Abeona Therapeutics initiated  »

Abeona Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

EOG

EOG Resources

09:15
01/23/18
01/23
09:15
01/23/18
09:15
Recommendations
EOG Resources analyst commentary  »

EOG Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FANG

Diamondback Energy

$132.21

4.64 (3.64%)

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Recommendations
Diamondback Energy analyst commentary  »

Diamondback Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

09:13
01/23/18
01/23
09:13
01/23/18
09:13
Hot Stocks
Twitter drops as COO Anthony Noto resigns to become SoFi CEO »

Shares of Twitter (TWTR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

AMRN

Amarin

$4.04

0.07 (1.76%)

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Amarin analyst commentary  »

Amarin shares have room…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DVN

Devon Energy

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Recommendations
Devon Energy analyst commentary  »

Devon Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TWTR

Twitter

09:12
01/23/18
01/23
09:12
01/23/18
09:12
Technical Analysis
Technical Take: Twitter drops on departure of COO Anthony Noto »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLR

Continental Resources

09:11
01/23/18
01/23
09:11
01/23/18
09:11
Recommendations
Continental Resources analyst commentary  »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXO

Concho Resources

$160.41

4.22 (2.70%)

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:09
01/23/18
01/23
09:09
01/23/18
09:09
Technical Analysis
Technical Take: Verizon trades higher after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ANAB

AnaptysBio

$114.78

-0.135 (-0.12%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$126.80

2.76 (2.23%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
Cimarex Energy analyst commentary  »

Cimarex Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    Feb

DGX

Quest Diagnostics

$103.57

0.51 (0.49%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Hot Stocks
Quest Diagnostics to acquire MedXM for undisclosed amount »

Quest Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:07
01/23/18
01/23
09:07
01/23/18
09:07
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SLB

Schlumberger

$79.79

3.37 (4.41%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$60.72

2.52 (4.33%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Anadarko analyst commentary  »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.